Studies have shown that active fund managers routinely underperform the S&P500 index*​

Milestone Pharmaceuticals Inc. (NASDAQ: MIST)

MIST Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
281.70%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%

MIST Stock Analysis

MIST PE Ratio:

MIST PEG Ratio: Not Available

MIST Forward EPS Growth (12 month): 0.00%

MIST PS Ratio: 61.1

MIST PSG Ratio: 0.2

MIST Forward Revenue Growth (12 month): 352.30%

MIST Articles

No data was found